References
- Grifflths CEM, Barker JNW. Psoriasis. In Burns T, Breathnach S, Cox N, Griffiths C, eds. Rook’s Textbook of Dermatology, 8th ed. UK: Wiley, Blackwell Science Ltd, 2010. p. 20.1.
- Martin D, Towne J. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133:17–26.
- Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129:1339–50.
- Fitch E, Harper E, Skorcheva I, et al. Pathophysiology of psoriasis: recent advances on IL-23 and TH17 cytokines. Curr Rheumatol Rep. 2007;9:461–7.
- Blauvelt A. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol. 2008;128:1064–7.
- Wong T, Hsu L, Liao W. Phototherapy in psoriasis: a review of mechanisms of action. J Cutan Med Surg. 2013;17:6–12.
- Dogra S, Kanwar A. Narrow band UVB phototherapy in dermatology. Indian J Dermatol Venereol Leprol. 2004;70:205–9.
- Ozawa M, Ferenczi K, Kikuchi T, et al. 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J Exp Med. 1999;189:711–8.
- Piskin G, Koomen CW Picavet D, et al. Ultraviolet-B irradiation decreases IFN-gamma and increases IL-4 expression in psoriatic lesional skin in situ and in cultured dermal T cells derived from these lesions. Exp Dermatol. 2003;12:172–80.
- Piskin G, Tursen U, Sylva-Steenland RMR, et al. Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-γ inducers – IL-12, IL-18 and IL-23. Exp Dermatol. 2004;13:764–72.
- Johnson-Huang LM, Suárez-Fariñas M, Sullivan-Whalen M, et al. Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. J Invest Dermatol. 2010;130:2654–63.
- Jacob SE, Nassiri M, Kerdel FA, et al. Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity. Mediators Inflamm. 2003;12:309–13.
- Takahashi H, Tsuji H, Hashimoto Y, et al. Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin Exp Dermatol. 2010;35:645–9.
- Coimbra S, Oliveira H, Reis F, et al. Growth factor and tumour necrosis factor-a levels in patients with psoriasis before, during and after psoralen – ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol. 2010;163:1282–90.
- Yilmaz SB, Cicek N, Coskun M, et al. Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. Arch Dermatol Res. 2012;304:465–9.
- Almakhzangy I, Gaballa A. Serum level of IL-17, IL-22, IFN-γ in patients with psoriasis. Egyptian Dermatol Online J. 2009;5:4.
- Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006;36:1309–23.
- Meephansan J, Ruchusatsawat K, Sindhupak W, et al. Effect of methotrexate on serum levels of IL-22 in patients with psoriasis. Eur J Dermatol. 2011;21:501–4.
- de Oliveira PSS, Cardoso PRG, Lima EV, et al. IL-17A, IL-22, IL-6, and IL-21 serum levels in plaque-type psoriasis in Brazilian patients. Mediators Inflamm. 2015;2015:819149.
- Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445:648–51.
- Krueger JG, Wolfe JT, Nabeya RT, et al. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med. 1995;182:2057–68.
- Coimbra S, Figueiredo A, Castro E, et al. The roles of cells and cytokines in the pathogenesis of psoriasis. Int J Dermatol. 2012;51:389–98.
- Michalak-Stoma A, Bartosińska J, Kowal M, et al. Serum levels of selected Th17 and Th22 cytokines in psoriatic patients. Dis Markers. 2013;35:625–31.
- Caproni M, Antiga E, Melani L, et al. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol. 2009;29:210–4.
- Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80:273–90.
- Nair RP, Ruether A, Stuart PE, et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol. 2008;128:1653–61.